Mapping-Guided Ablation for Persistent Atrial Fibrillation (MAP-AF): A Multicenter, Single-Blind, Randomized Controlled Trial
Circulation: Arrhythmia and Electrophysiology · 2024-08 · 17 (8)
DOI: 10.1161/circep.124.012829 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Circulation: Arrhythmia and Electrophysiology, 2024-08. Verfasst von Yoshihide Takahashi und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, Graduate School of Medical and Dental Sciences (Y.T., M.G., T.S.). Hauptthemen laut MEDLINE: Atrial Fibrillation, Catheter Ablation, Pulmonary Veins. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 22 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: The clinical outcome of pulmonary vein isolation (PVI) for persistent atrial fibrillation (AF) is suboptimal. Mapping studies have demonstrated atrial sites outside of the pulmonary veins displaying focal activation patterns during AF. We sought to determine whether adding catheter ablation of focal activation sites to PVI improves clinical outcomes of catheter ablation for persistent AF. METHODS: In this multicenter, randomized, single-blinded trial, we assigned patients with persistent AF to either PVI alone or to mapping-guided ablation of focal activation sites in addition to PVI in a 1:1 ratio. In the mapping-guided group, both atria were mapped after PVI using a Pentaray catheter (Biosense-Webster) and focal activation sites identified by CARTOFINDER (Biosense-Webster) were ablated. The primary end point was freedom from AF or atrial tachycardia without antiarrhythmic drugs beyond a 90-day blanking period. RESULTS: A total of 98 patients were assigned to the mapping-guided group and 102 to the PVI alone group. In the mapping-guided group, focal activation sites were identified at 2.6±0.3 and 2.5±0.2 sites per patient in the left and right atrium, respectively. Patients were followed up for 768.5 (interquartile range, 723.75–915.75) and 755.5 days (interquartile range, 728.5–913.75) in the mapping-guided ablation and the PVI alone groups, respectively. Freedom from AF/atrial tachycardia without antiarrhythmic drugs at 2-year follow-up was 66.8% and 75.2% in the mapping-guided ablation and the PVI alone groups, respectively (hazard ratio, 1.26 [95% CI, 0.76–2.10]; P =0.37). Adverse events occurred in 3 patients (3.0%) and none (0%) in the mapping-guided ablation and the PVI alone groups, respectively ( P =0.12). CONCLUSIONS: In patients with persistent AF, the addition of mapping-guided ablation of focal activation sites to PVI did not improve clinical outcomes compared with PVI alone. REGISTRATION: URL: https://center6.umin.ac.jp/cgi-open-bin/ctr/index.cgi?function=02 ; Unique identifier: UMIN000037569.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiovascular Medicine, Graduate School of Medical and Dental Sciences (Y.T., M.G., T.S.).
- Department of Cardiology, Shin-Yurigaoka General Hospital, Kawasaki (Y.T.).
- Department of Cardiology, Kobe City Medical Center General Hospital, Japan (A.K.).
- Department of Cardiology, Kokura Memorial Hospital, Japan (K.H.).
- Department of Cardiovascular Medicine, Toyohashi Heart Center, Japan (Y.S.).
- Department of Cardiology, Hirosaki University Graduate School of Medicine, Japan (M.K.).
ORCID-Profile: Yoshihide Takahashi, Atsushi Kobori, Masaomi Kimura, Osamu Inaba, Kojiro Tanimoto, Ryoichi Hanazawa, Akihiro Hirakawa, Masahiko Goya, Tetsuo Sasano
Zitieren
APA
Takahashi, Y., Kobori, A., Hiroshima, K., Sakamoto, Y., Kimura, M., Inaba, O., Tanimoto, K., Hanazawa, R., Hirakawa, A., Goya, M., & Sasano, T. (2024). Mapping-Guided Ablation for Persistent Atrial Fibrillation (MAP-AF): A Multicenter, Single-Blind, Randomized Controlled Trial. Circulation: Arrhythmia and Electrophysiology, 17(8). https://doi.org/10.1161/circep.124.012829
Vancouver
Takahashi Y, Kobori A, Hiroshima K, Sakamoto Y, Kimura M, Inaba O, et al. Mapping-Guided Ablation for Persistent Atrial Fibrillation (MAP-AF): A Multicenter, Single-Blind, Randomized Controlled Trial. Circulation: Arrhythmia and Electrophysiology. 2024;17(8). doi:10.1161/circep.124.012829
BibTeX
@article{Takahashi2024,
author = {Takahashi, Yoshihide and Kobori, Atsushi and Hiroshima, Kenichi and Sakamoto, Yuichiro and Kimura, Masaomi and Inaba, Osamu and Tanimoto, Kojiro and Hanazawa, Ryoichi and Hirakawa, Akihiro and Goya, Masahiko and Sasano, Tetsuo},
title = {Mapping-Guided Ablation for Persistent Atrial Fibrillation (MAP-AF): A Multicenter, Single-Blind, Randomized Controlled Trial},
journal = {Circulation: Arrhythmia and Electrophysiology},
year = {2024},
volume = {17},
number = {8},
doi = {10.1161/circep.124.012829}
}
EUVIMED